Diagnostic antibodies and antigens for Liver Diseases testing: Hyaluronic acid (HA), laminins (LN), collagen type IV (cIV), Procollagen III N-terminal peptide (PIIINP), Lithocholic Acid (LCA), deoxycholic acid (cholanoic acid), hyaluronic acid (HA), Cholyglycine (CG), Prealbumin (PA)
Liver is an important organ and it is responsible for the metabolism, energy storage, and waste filtering. Liver disease is a generally designates to any condition that affects the liver. These conditions may be because of different reasons, but all these reasons damage the liver and affect its function. Many people with liver disease do not cause any symptoms in the early stages. At a certain point in the development of liver disease damage can become irreversible and lead to liver failure, liver cancer, or death. Early diagnosis of liver disease may prevent liver damage. GENEMEDI produces core diagnostic ingredients such as collagen type IV, Procollagen III N-terminal peptide, Lithocholic Acid, deoxycholic acid, hyaluronic acid, Cholyglycine, Prealbumin and so on for test of Liver Diseases and related syndrome using ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT Kit.
Classification:
HABP
LN
cIV
PIIINP
LCA
cholanoic acid
HA
CG
PA
Hyaluronic acid binding protein (HABP)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-h-HABP | Human | Hyaluronic acid binding protein (HABP) | rheumatoid arthritis (RA) andosteoarthritis | GMP-h-HABP-Ag01: Hyaluronic acid binding protein (HABP) |
Hyaluronic acid (HA) Antibody Binding, Immunogen in Sandwich ELISA test, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. | GMP-h-HABP-Ab01; GMP-h-HABP-Ab02: Anti-Hyaluronic acid binding protein (HABP) mouse monoclonal antibody(mAb) |
Human Hyaluronic acid (HA) protein binding, ELISA validated as capture antibody and detection antibody. Pair in HAlevel test and Liver Diseases/Fibrosis evaluation. | ![]() |
laminins (LN)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-h-LN | Human | laminins (LN) | muscular dystrophy, lethal skin blistering disease (junctional epidermolysis bullosa) and nephrotic syndrome | GMP-h-LN-Ag01: Recombinant human LN Protein |
laminins (LN) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in LN level test of Liver diseases(muscular dystrophy, lethal skin blistering disease (junctional epidermolysis bullosa) and nephrotic syndrome) and related syndrome evaluation. | GMP-h-LN-Ab01; GMP-h-LN-Ab02: Anti-human LN mouse monoclonal antibody(mAb) |
Human laminins (LN) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other laminins (LN) antibodies in LN level test of Liver diseases (muscular dystrophy, lethal skin blistering disease (junctional epidermolysis bullosa) and nephrotic syndrome) and related syndrome evaluation. | ![]() |
collagen type IV (cIV)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-h-cIV | Human | collagen type IV (cIV) | Goodpasture syndrome, Alport syndrome, glomerular basement membrane, Liver fibrosis and cirrhosis, alcoholic liver disease, hepatitis C and fall following successful therapy. autosomal dominant hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. porencephaly, schizencephaly, congenital cataract, coronary artery disease, diabetic nephropathy and renal injury. | GMP-h-cIV-Ag01: Recombinant human cIV Protein |
collagen type IV (cIV) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in cIV level test of Liver diseases(Goodpasture syndrome, Alport syndrome, glomerular basement membrane, Liver fibrosis and cirrhosis, alcoholic liver disease, hepatitis C and fall following successful therapy. autosomal dominant hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. porencephaly, schizencephaly, congenital cataract, coronary artery disease, diabetic nephropathy and renal injury.) and related syndrome evaluation. | GMP-h-cIV-Ab01; GMP-h-cIV-Ab02: Anti-human cIV mouse monoclonal antibody(mAb) |
Human collagen type IV (cIV) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other collagen type IV (cIV) antibodies in cIV level test of Liver diseases (Goodpasture syndrome, Alport syndrome, glomerular basement membrane, Liver fibrosis and cirrhosis, alcoholic liver disease, hepatitis C and fall following successful therapy. autosomal dominant hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. porencephaly, schizencephaly, congenital cataract, coronary artery disease, diabetic nephropathy and renal injury.) and related syndrome evaluation. | ![]() |
Procollagen III N-terminal peptide (PIIINP)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-h-PIIINP | Human | Procollagen III N-terminal peptide (PIIINP) | liver fibrosis and cirrhosis | GMP-h-PIIINP-Ag01: Recombinant human PIIINP Protein |
Procollagen III N-terminal peptide (PIIINP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in PIIINP level test of Liver diseases(liver fibrosis and cirrhosis) and related syndrome evaluation. | GMP-h-PIIINP-Ab01; GMP-h-PIIINP-Ab02: Anti-human PIIINP mouse monoclonal antibody(mAb) |
Human Procollagen III N-terminal peptide (PIIINP) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Procollagen III N-terminal peptide (PIIINP) antibodies in PIIINP level test of Liver diseases (liver fibrosis and cirrhosis) and related syndrome evaluation. | ![]() |
Lithocholic Acid (LCA)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-SMT-LCA | Human | Lithocholic Acid (LCA) | liver damage | GMP-SMT-LCA-Ag01: BSA-Lithocholic Acid (LCA); GMP-SMT-LCA-Ag02: OVA-Lithocholic Acid (LCA) |
Competitive immunoassay-validated hapten-carrier conjugates [BSA-&OVA-Lithocholic Acid (LCA)], Lithocholic Acid (LCA) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in LCA level test of Liver diseases (liver damage) and related syndrome evaluation. | GMP-SMT-LCA-Ab01: Anti-Lithocholic Acid (LCA) mouse monoclonal antibody(mAb) |
Human Lithocholic Acid (LCA) binding, in Competitive immunoassay validation, Elisa, lateral-flow tests, and other immunoassays in LCA level test of Liver diseases (liver damage) and related syndrome evaluation. | ![]() |
deoxycholic acid (cholanoic acid)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-SMT-cholanoic-acid | Human | deoxycholic acid (cholanoic acid) | liver cirrhosis, chronic kidney disease, vascular calcification, vasculature toxicity | GMP-SMT-cholanoic-acid-Ag01: BSA-deoxycholic acid (cholanoic acid); GMP-SMT-cholanoic-acid-Ag02: OVA-deoxycholic acid (cholanoic acid) |
Competitive immunoassay-validated hapten-carrier conjugates [BSA-&OVA-deoxycholic acid (cholanoic acid)], deoxycholic acid (cholanoic acid) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in cholanoic acid level test of Liver diseases (liver cirrhosis, chronic kidney disease, vascular calcification, vasculature toxicity) and related syndrome evaluation. | GMP-SMT-cholanoic-acid-Ab01: Anti-deoxycholic acid (cholanoic acid) mouse monoclonal antibody(mAb) |
Human deoxycholic acid (cholanoic acid) binding, in Competitive immunoassay validation, Elisa, lateral-flow tests, and other immunoassays in cholanoic acid level test of Liver diseases (liver cirrhosis, chronic kidney disease, vascular calcification, vasculature toxicity) and related syndrome evaluation. | ![]() |
hyaluronic acid (HA)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-SMT-HA | Human | hyaluronic acid (HA) | GMP-SMT-HA-Ag01: BSA-hyaluronic acid (HA); GMP-SMT-HA-Ag02: OVA-hyaluronic acid (HA) |
Competitive immunoassay-validated hapten-carrier conjugates [BSA-&OVA-hyaluronic acid (HA)], hyaluronic acid (HA) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in HA level test of Liver diseases and related syndrome evaluation. | GMP-SMT-HA-Ab01: Anti-hyaluronic acid (HA) mouse monoclonal antibody(mAb) |
Human hyaluronic acid (HA) binding, in Competitive immunoassay validation, Elisa, lateral-flow tests, and other immunoassays in HA level test of Liver diseases and related syndrome evaluation. | ![]() |
Cholyglycine (CG)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-SMT-CG | Human | Cholyglycine (CG) | liver cirrhosis or obstructive liver disease | GMP-SMT-CG-Ag01: BSA-Cholyglycine (CG) GMP-SMT-CG-Ag02: OVA-Cholyglycine (CG) |
Competitive immunoassay-validated hapten-carrier conjugates [BSA-&OVA-Cholyglycine (CG)], Cholyglycine (CG) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in CG level test of Liver diseases (liver cirrhosis or obstructive liver disease) and related syndrome evaluation. | GMP-SMT-CG-Ab01: Anti-Cholyglycine (CG) mouse monoclonal antibody(mAb) |
Human Cholyglycine (CG) binding, in Competitive immunoassay validation, Elisa, lateral-flow tests, and other immunoassays in CG level test of Liver diseases (liver cirrhosis or obstructive liver disease) and related syndrome evaluation. | ![]() |
Prealbumin (PA)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-h-PA | Human | Prealbumin (PA) | liver disease, inflammation, or tissue death | GMP-h-PA-Ag01: Recombinant human PA Protein |
Prealbumin (PA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in PA level test of Liver diseases(liver disease, inflammation, or tissue death) and related syndrome evaluation. | GMP-h-PA-Ab01; GMP-h-PA-Ab02: Anti-human PA mouse monoclonal antibody(mAb) |
Human Prealbumin (PA) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Prealbumin (PA) antibodies in PA level test of Liver diseases (liver disease, inflammation, or tissue death) and related syndrome evaluation. | ![]() |